Application No.: 10/092750 Docket No.: COTH-P01-518

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Currently Amended) A substantially pure human Bcl-X_L-binding polypeptide, said polypeptide emprising the sequence selected from the group consisting of the sequence of any of SEQ ID NOS: 4-50, and 63-71, and 224-228.
- 2. (Previously Presented) A substantially pure human Bcl-X_L-binding polypeptide, said polypeptide comprising the sequence selected from the group consisting of SEQ ID NOS: 51-62, 229, and 230.
- 3-26. (Cancelled).
- 27. (New) A substantially pure human Bcl-X_L-binding polypeptide, said polypeptide consisting of the sequence of any of SEQ ID NOS: 224-228.
- 28. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 51.
- 29. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 52.
- 30. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 53.
- 31. (New) The substantially pure human Bcl- X_L -binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 54.
- 32. (New) The substantially pure human Bcl- X_L -binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 55.
- 33. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 56.
- 34. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 57.

Application No.: 10/092750 Docket No.: COTH-P01-518

35. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 58.

- 36. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 59.
- 37. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 60.
- 38. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 61.
- 39. (New) The substantially pure human Bcl- X_L -binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 62.
- 40. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 229.
- 41. (New) The substantially pure human Bcl-X_L-binding polypeptide of claim 2, wherein said polypeptide comprising the sequence of SEQ ID NO: 230.